HC Wainwright Estimates Tourmaline Bio Q2 Earnings

Tourmaline Bio, Inc. (NASDAQ:TRML - Free Report) - HC Wainwright issued their Q2 2026 earnings per share (EPS) estimates for Tourmaline Bio in a note issued to investors on Monday, May 5th. HC Wainwright analyst Y. Chen expects that the company will post earnings of ($0.94) per share for the quarter. HC Wainwright has a "Buy" rating and a $50.00 price objective on the stock. The consensus estimate for Tourmaline Bio's current full-year earnings is ($3.02) per share. HC Wainwright also issued estimates for Tourmaline Bio's FY2026 earnings at ($3.79) EPS.

Tourmaline Bio (NASDAQ:TRML - Get Free Report) last issued its quarterly earnings results on Friday, May 2nd. The company reported ($0.89) EPS for the quarter, beating the consensus estimate of ($0.91) by $0.02.

TRML has been the subject of a number of other reports. Wedbush boosted their price objective on Tourmaline Bio from $42.00 to $43.00 and gave the stock an "outperform" rating in a research report on Friday, March 14th. Lifesci Capital started coverage on shares of Tourmaline Bio in a report on Monday, February 24th. They set an "outperform" rating and a $58.00 price target for the company. Finally, Chardan Capital restated a "buy" rating and issued a $70.00 price objective on shares of Tourmaline Bio in a report on Monday. Seven research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company has a consensus rating of "Buy" and a consensus price target of $49.33.

Tourmaline Bio Trading Up 2.3 %

TRML traded up $0.35 on Tuesday, hitting $15.74. 133,574 shares of the company were exchanged, compared to its average volume of 271,046. The firm has a 50-day moving average price of $15.43 and a two-hundred day moving average price of $18.87. Tourmaline Bio has a twelve month low of $11.56 and a twelve month high of $29.79. The company has a market cap of $404.28 million, a price-to-earnings ratio of -5.58 and a beta of 2.11.

Institutional Investors Weigh In On Tourmaline Bio

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Brooklyn Investment Group acquired a new position in Tourmaline Bio in the 4th quarter valued at $32,000. Tower Research Capital LLC TRC boosted its stake in shares of Tourmaline Bio by 297.6% in the fourth quarter. Tower Research Capital LLC TRC now owns 1,646 shares of the company's stock valued at $33,000 after buying an additional 1,232 shares in the last quarter. KLP Kapitalforvaltning AS acquired a new position in Tourmaline Bio during the fourth quarter worth $47,000. Virtus ETF Advisers LLC purchased a new position in Tourmaline Bio in the fourth quarter worth $64,000. Finally, GAMMA Investing LLC lifted its holdings in Tourmaline Bio by 4,481.7% in the first quarter. GAMMA Investing LLC now owns 7,514 shares of the company's stock valued at $114,000 after acquiring an additional 7,350 shares during the period. 91.89% of the stock is owned by hedge funds and other institutional investors.

Tourmaline Bio Company Profile

Tourmaline Bio, Inc operates as a clinical biotechnology company that develops medicines for patients with life-altering immune and inflammatory diseases. It develops TOUR006, a human anti-IL-6 monoclonal antibody that selectively binds to interleukin-6, a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders.